Oliver Weld Bayer, Ella Winter, Louise Dickinson Rich, Joseph Harrington, Alexandra Kropotkin, Paul Gallico, Robert Ormond Case, Frank W. Brock, Wayne Parrish, T. E. Murphy, John Kobler, Eric Devine, Elizabeth Wilson, Harriet Gould,
... Familiar Her Public Thought They Knew All about Franchette Signy, the Fabulous Hollywood Glamour Girl—But Only ...
1943 - Gale Group | LibertyMagazine
Shanly C. Seferina, Bram Ramaekers, Maaike de Boer, M. Wouter Dercksen, Franchette van den Berkmortel, Roel J.W. van Kampen, Agnès J. van de Wouw, Adri C. Voogd, Vivianne Heijnen, Manuela Joore,
... de Boer 1,2 , M. Wouter Dercksen 3 , Franchette van den Berkmortel 4 , Roel J.W. van ...
Tópico(s): Monoclonal and Polyclonal Antibodies Research
2017 - Impact Journals LLC | Oncotarget
D.J.A. Lobbezoo, Wilfred Truin, Adri C. Voogd, Rudi M. H. Roumen, Gerard Vreugdenhil, M. Wouter Dercksen, Franchette van den Berkmortel, Tineke J. Smilde, A. van de Wouw, Roel van Kampen, Johanna van Riel, Natascha A. J. B. Peters, Petronella G.M. Peer, Vivianne C. G. Tjan‐Heijnen,
... Gerard Vreugdenhil 1, 2 , Marcus Wouter Dercksen 2 , Franchette van den Berkmortel 4 , Tineke Smilde 5 , Agnes ...
Tópico(s): Cancer Treatment and Pharmacology
2016 - Impact Journals LLC | Oncotarget
Christian U Blank, Minke W Lucas, Richard A. Scolyer, Bart A van de Wiel, Alexander M Menzies, Marta Lopez-Yurda, Lotte L Hoeijmakers, Robyn P M Saw, Judith M Lijnsvelt, Nigel G Maher, Saskia M Pulleman, Maria Gonzalez, Alejandro Torres Acosta, Winan J. van Houdt, Serigne N Lo, Anke M J Kuijpers, Andrew Spillane, W Martin C Klop, Thomas E Pennington, Charlotte L Zuur, Kerwin F Shannon, Beatrijs A Seinstra, Robert V Rawson, John B A G Haanen, Sydney Ch'ng, Kishan A T Naipal, Jonathan Stretch, Johannes V van Thienen, Michael A Rtshiladze, Sofie Wilgenhof, Rony Kapoor, Aafke Meerveld-Eggink, Lindsay G Grijpink-Ongering, Alexander C.J. van Akkooi, Irene L M Reijers, David E Gyorki, Dirk J Grünhagen, Frank M Speetjens, Sonja B Vliek, Joanna Placzke, Lavinia Spain, Robert C Stassen, Mona Amini-Adle, Céleste Lebbé, Mark B Faries, Caroline Robert, Paolo A. Ascierto, Rozemarijn van Rijn, Franchette W P J van den Berkmortel, Djura Piersma, Andre van der Westhuizen, Gerard Vreugdenhil, Maureen J B Aarts, Marion A M Stevense-den Boer, Victoria Atkinson, Muhammad Khattak, Miles C Andrews, Alfons J M van den Eertwegh, Marye J Boers-Sonderen, Geke A P Hospers, Matteo S Carlino, Jan-Willem B de Groot, Ellen Kapiteijn, Karijn P M Suijkerbuijk, Piotr Rutkowski, Shahneen Sandhu, Astrid A M van der Veldt, Georgina V Long,
BackgroundPhase 1–2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy.MethodsIn this phase 3 trial, we randomly assigned patients with resectable, macroscopic stage III melanoma, in a 1:1 ratio, to receive two cycles of neoadjuvant ipilimumab plus nivolumab and then undergo surgery or to undergo surgery and then receive 12 cycles of adjuvant nivolumab. Only the patients in the neoadjuvant ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2024 - Massachusetts Medical Society | New England Journal of Medicine
Produção Nacional
Revisado por pares
Rik J. Verheijden, F.H. Burgers, Josephine C Janssen, Anouk E Putker, S. Veenstra, Geke A.P. Hospers, Maureen J.B. Aarts, Karel W Hehenkamp, Veerle L E Doornebosch, Marthe Verhaert, Franchette W.P.J. van den Berkmortel, Katerina Chatzidionysiou, Arturo Llobell, Milton Barros, Alexandre T J Maria, Akari Takeji, José-Salvador García Morillo, Merav Lidar, Mick J M van Eijs, Christian U. Blank, Sandrine Aspeslagh, Djura Piersma, Ellen Kapiteijn, Mariëtte Labots, Marye J. Boers‐Sonderen, Astrid A.M. van der Veldt, John B.A.G. Haanen, Anne M. May, Karijn P M Suijkerbuijk,
Recent studies indicate an association between immunosuppression for immune-related adverse events (irAEs) and impaired survival in patients who received immune checkpoint inhibitors. Whether this is related to corticosteroids or second-line immunosuppressants is unknown. In the largest cohort thus far, we assessed the association of immunosuppressant type and dose with survival in melanoma patients with irAEs.
Tópico(s): Melanoma and MAPK Pathways
2024 - Elsevier BV | European Journal of Cancer
Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia M. Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke Boedker Holmstroem, Lidwina D.V. Wever, M. van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, A. Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A. M. Stevense‐den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan‐Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers‐Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebæk, Lisbet Rosenkrantz Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, A. Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen,
Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma.In this phase 3, multicenter, open-label trial, we randomly assigned patients with unresectable ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2022 - Massachusetts Medical Society | New England Journal of Medicine
Olivier J. van Not, Rik J. Verheijden, Alfonsus J.M. van den Eertwegh, John B.A.G. Haanen, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers‐Sonderen, Jan‐Willem B. de Groot, Geke A.P. Hospers, Anna M. Kamphuis, Ellen Kapiteijn, Anne M. May, Melissa M. de Meza, Djura Piersma, Rozemarijn van Rijn, Marion Stevense, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Willeke A.M. Blokx, Michel J. M. Wouters, Karijn P.M. Suijkerbuijk,
Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy.To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy.This population-based, ...
Tópico(s): CAR-T cell therapy research
2022 - American Medical Association | JAMA Oncology
Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jesper van Breeschoten, Jan‐Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Marion A. M. Stevense‐den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Han J. Bonenkamp, Marye J. Boers‐Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk,
Recent reports suggest the limited efficacy of immune checkpoints inhibitors in advanced acral melanoma (AM). This study aims to investigate the clinical outcomes of immune checkpoint inhibitors in patients with stage III and IV AM and compare them to cutaneous melanoma (CM).We included patients with advanced AM and CM treated with first-line anti-programmed cell death (PD)-1 monotherapy or ipilimumab-nivolumab registered in the prospective nationwide Dutch Melanoma Treatment Registry. Objective response ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2022 - Elsevier BV | European Journal of Cancer
Rawa K. Ismail, Karijn P.M. Suijkerbuijk, Anthonius de Boer, Maaike van Dartel, Doranne L. Hilarius, Anna M.G. Pasmooij, Michiel C.T. van Zeijl, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, John B.A.G. Haanen, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Astrid A.M. van der Veldt, Art Vreugdenhil, Hans M. Westgeest, Alfons J. van den Eertwegh, Michel W.J.M. Wouters,
Recent results of patients with advanced melanoma treated with first-line BRAF-MEK inhibitors in clinical trials showed 5-year survival in one-third of patients with a median overall survival (OS) of more than 2 years. This study aimed to investigate these patients' real-world survival and identify the characteristics of long-term survivors. The study population consisted of patients with advanced cutaneous melanoma with a BRAF-V600 mutated tumor who were treated with first-line BRAF-MEK inhibitors ...
Tópico(s): HER2/EGFR in Cancer Research
2022 - Lippincott Williams & Wilkins | Melanoma Research
Olivier J. van Not, Jesper van Breeschoten, Alfonsus J.M. van den Eertwegh, Doranne L. Hilarius, Melissa M. de Meza, John B.A.G. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion A. M. Stevense‐den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers‐Sonderen, Willeke A.M. Blokx, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters,
Abstract The COVID‐19 pandemic had a severe impact on medical care. Our study aims to investigate the impact of COVID‐19 on advanced melanoma care in the Netherlands. We selected patients diagnosed with irresectable stage IIIc and IV melanoma during the first and second COVID‐19 wave and compared them with patients diagnosed within the same time frame in 2018 and 2019. Patients were divided into three geographical regions. We investigated baseline characteristics, time from diagnosis until start ...
Tópico(s): Cutaneous Melanoma Detection and Management
2021 - Wiley | International Journal of Cancer
M Franken, B Leeneman, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel, M. J. Boers‐Sonderen, A.J.M. van den Eertwegh, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, R.S. van Rijn, Karijn P.M. Suijkerbuijk, Astrid A.M. van der Veldt, Hans M. Westgeest, Michel W.J.M. Wouters, John B.A.G. Haanen, Carin A. Uyl‐de Groot,
•The median survival of patients with metastatic melanoma increased from 11.8 months in 2013 to 21.1 months in 2018.•The gain in survival came along with substantial health care costs; health care costs were on average €100 300 per patient.•Costs were much higher for patients with systemic treatment (€118 905) than for patients without systemic treatment (€8316).•Costs for patients who received systemic treatment remained stable even after the introduction of additional novel drugs.•Insights into the ...
Tópico(s): Health Systems, Economic Evaluations, Quality of Life
2021 - Elsevier BV | ESMO Open
Michiel C.T. van Zeijl, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, Liesbeth C. de Wreede, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan‐Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Jacobus J. M. van der Hoeven, John B.A.G. Haanen,
Abstract There is no consensus on the optimal treatment duration of anti‐PD‐1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti‐PD‐1 discontinuation, the association of treatment duration with progression and anti‐PD‐1 re‐treatment in relapsing patients. Analyses were performed on advanced melanoma patients in the Netherlands who discontinued first‐line anti‐PD‐1 monotherapy in the absence of progressive disease (n = 324). Survival was estimated after anti‐PD‐ ...
Tópico(s): Immunotherapy and Immune Responses
2021 - Wiley | International Journal of Cancer
Monique K. Van der Kooij, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers‐Sonderen, Jesper van Breeschoten, Alfonsus J.M. van den Eertwegh, Jan Willem B. de Groot, John B.A.G. Haanen, Geke A.P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Michiel C.T. van Zeijl, Michel W.J.M. Wouters, Olaf M. Dekkers, Ellen Kapiteijn,
Because immune checkpoint inhibition (ICI) can cause immune-related adverse events (irAEs) mimicking immunologic diseases, patients with preexisting autoimmune disease (AID) have been excluded from clinical trials.To evaluate the safety and efficacy of ICI in patients with advanced melanoma with and without AID.Nationwide cohort study.The Netherlands.4367 patients with advanced melanoma enrolled in the Dutch Melanoma Treatment Registry (DMTR) between July 2013 and July 2018 and followed through February ...
Tópico(s): Melanoma and MAPK Pathways
2021 - American College of Physicians | Annals of Internal Medicine
Melissa M. de Meza, Rawa K. Ismail, Daan Jan Willem Rauwerdink, Olivier J. van Not, Jesper van Breeschoten, Willeke A.M. Blokx, Anthonius de Boer, Maaike van Dartel, Doranne L. Hilarius, Eva Ellebæk, Han J. Bonenkamp, Christian U. Blank, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, John B.A.G. Haanen, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Astrid A.M. van der Veldt, Art Vreugdenhil, Hans M. Westgeest, Alfons J.M. van den Eertwegh, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters,
BackgroundLittle is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, adjuvant-treated melanoma patients have been registered in the DMTR, a population-based registry to monitor the quality and safety of melanoma care in the Netherlands. This study aims to describe treatment patterns, relapse, and toxicity rates of adjuvant-treated melanoma patients beyond the clinical trial setting.MethodsAnalyses were performed on adjuvant-treated melanoma ...
Tópico(s): Immunotherapy and Immune Responses
2021 - Elsevier BV | European Journal of Cancer
Evalyn E.A.P. Mulder, Karlijn de Joode, Saskia Litière, Albert J. ten Tije, Karijn P.M. Suijkerbuijk, M. J. Boers‐Sonderen, Geke A.P. Hospers, Jan Willem B. de Groot, A.J.M. van den Eertwegh, Maureen J.B. Aarts, Djura Piersma, R.S. van Rijn, Ellen Kapiteijn, Gerard Vreugdenhil, Franchette W.P.J. van den Berkmortel, Esther Oomen‐de Hoop, M Franken, Bettina Ryll, Piotr Rutkowski, Stefan Sleijfer, John B.A.G. Haanen, Astrid A.M. van der Veldt,
Abstract Background The introduction of programmed cell death protein 1 (PD-1) blockers (i.e. nivolumab and pembrolizumab) has significantly improved the prognosis of patients with advanced melanoma. However, the long treatment duration (i.e. two years or longer) has a high impact on patients and healthcare systems in terms of (severe) toxicity, health-related quality of life (HRQoL), resource use, and healthcare costs. While durable tumour responses have been observed and PD-1 blockade is discontinued ...
Tópico(s): Cutaneous Melanoma Detection and Management
2021 - BioMed Central | BMC Cancer
Maaike Biewenga, Monique K. Van der Kooij, Michel W.J.M. Wouters, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Marye J. Boers‐Sonderen, Geke A.P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, John B.A.G. Haanen, Alfons J. M. van der Eertwegh, Bart van Hoek, Ellen Kapiteijn,
Checkpoint inhibitor-induced hepatitis is an immune-related adverse event of programmed cell death protein 1 (PD-1) inhibition, cytotoxic T-lymphocyte associated 4 (CTLA-4) inhibition or the combination of both. Aim of this study was to assess whether checkpoint inhibitor-induced hepatitis is related to liver metastasis and outcome in a real-world nationwide cohort.Data from the prospective nationwide Dutch Melanoma Treatment Registry (DMTR) was used to analyze incidence, risk factors of checkpoint ...
Tópico(s): Colorectal Cancer Treatments and Studies
2021 - Springer Science+Business Media | Hepatology International
Nienke A. de Glas, Esther Bastiaannet, Frederiek van den Bos, Simon P. Mooijaart, Astrid A.M. van der Veldt, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers‐Sonderen, Alfonsus J.M. van den Eertwegh, Jan‐Willem B. de Groot, John B.A.G. Haanen, Geke A.P. Hospers, Mathilde Jalving, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Michel W.J.M. Wouters, Johanneke E.A. Portielje, Ellen Kapiteijn,
Background: Previous trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included. The aim of this study was to describe the treatment patterns and outcomes of “real-world” older patients with metastatic melanoma and to identify predictors of outcome. Methods: We included patients aged ≥65 years with metastatic melanoma from the Dutch Melanoma Treatment Registry. We described the reasons for hospital ...
Tópico(s): Melanoma and MAPK Pathways
2021 - Multidisciplinary Digital Publishing Institute | Cancers
Jesper van Breeschoten, Michel W.J.M. Wouters, Doranne L. Hilarius, John B.A.G. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan‐Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Karijn P.M. Suijkerbuijk, Willeke A.M. Blokx, Bert-Jan J. ten Tije, Astrid A.M. van der Veldt, Art Vreugdenhil, Marye J. Boers‐Sonderen, Alfonsus J.M. van den Eertwegh,
Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced BRAFV600-mutant melanoma patients. We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAFV600-mutation ...
Tópico(s): CAR-T cell therapy research
2021 - Springer Nature | British Journal of Cancer
Emerens Wensink, Marloes A.G. Elferink, Anne M. May, Linda Mol, Patricia A. H. Hamers, Sandra D. Bakker, Geert-Jan Creemers, Jan Willem B. de Groot, G. J. de Klerk, Brigitte C.M. Haberkorn, A. Haringhuizen, Ronald Hoekstra, Jarmo Hunting, Emile D. Kerver, Daniëlle Mathijssen‐van Stein, Marco B. Polée, Hans Pruijt, Patricia Quarles van Ufford-Mannesse, Sandra A. Radema, R. C. Rietbroek, Lieke H. J. Simkens, Bea C. Tanis, Daan ten Bokkel Huinink, Manuel L. R. Tjin‐A‐Ton, Cathrien S. Tromp-van Driel, Monique M. Troost, Agnès J. van de Wouw, Franchette W.P.J. van den Berkmortel, Anke J. M. van der Pas, Ankie M.T. van der Velden, Marjan A. van Dijk, Joyce M. van Dodewaard-de Jong, Edith B. van Druten, Theo van Voorthuizen, G.J. Veldhuis, Henk M.W. Verheul, Hanneke J. H. M. J. Vestjens, Jeroen Vincent, Onno Kranenburg, Cornelis J.A. Punt, Geraldine R. Vink, Jeanine Roodhart, Miriam Koopman,
Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy.Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer ...
Tópico(s): Colorectal Cancer Treatments and Studies
2020 - Springer Nature | British Journal of Cancer
Michiel C.T. van Zeijl, John B.A.G. Haanen, Michel W.J.M. Wouters, Liesbeth C. de Wreede, Anouk Jochems, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Koos J.M. van der Hoeven, Alfons J.M. van den Eertwegh,
The efficacy of anti-programmed death-1 (PD-1) monotherapy for advanced melanoma has been established, but it is unknown to what extent patients benefit in the real world. In this observational study with nationwide population-based data from the Dutch Melanoma Treatment Registry, we analyzed real-world outcomes of first-line anti-PD-1 monotherapy in advanced melanoma patients diagnosed in 2015 to 2016. Overall survival (OS) was estimated with the Kaplan-Meier method. Competing risks analysis was ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2020 - Lippincott Williams & Wilkins | Journal of Immunotherapy
B Leeneman, Carin A. Uyl‐de Groot, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel, Alfons J.M. van den Eertwegh, Jan Willem B. de Groot, Karin H. Herbschleb, Jacobus J. M. van der Hoeven, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Michel W.J.M. Wouters, John B.A.G. Haanen, M Franken,
Immunotherapeutic and targeted drugs improved survival of patients with metastatic melanoma. There is, however, a lack of evidence regarding their healthcare costs in clinical practice. The aim of our study was to provide insight into real-world healthcare costs of patients with metastatic cutaneous melanoma. Data were obtained from the Dutch Melanoma Treatment Registry for patients who were registered between July 2012 and December 2018. Mean total/monthly costs per patient were reported for all ...
Tópico(s): Cancer Immunotherapy and Biomarkers
2020 - Multidisciplinary Digital Publishing Institute | Cancers
Rik J. Verheijden, Anne M. May, Christian U. Blank, Astrid A.M. van der Veldt, Marye J. Boers‐Sonderen, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Alfonsus J.M. van den Eertwegh, Jan Willem B. de Groot, Jacobus J. M. van der Hoeven, Geke A.P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Michiel C.T. van Zeijl, Michel W.J.M. Wouters, John B.A.G. Haanen, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk,
BackgroundImmune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adverse events (irAEs). Since these irAEs mimick immunological disease, a female predominance has been speculated on. Nevertheless, no demographic or tumour-related factors associated with an increased risk of irAEs have been identified until now.MethodsRisk ratios of severe (grade ≥3) irAEs for age, sex, WHO performance status, number of comorbidities, stage of disease, number of metastases and serum lactate ...
Tópico(s): Peptidase Inhibition and Analysis
2020 - Elsevier BV | ESMO Open
Michiel C.T. van Zeijl, Liesbeth C. de Wreede, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, Anouk Jochems, Maartje G. Schouwenburg, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, R.S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Jacobus J. M. van der Hoeven, John B.A.G. Haanen,
Background The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time in daily clinical practice. Methods From a Dutch nationwide population-based registry, patients with advanced melanoma diagnosed from 2013 to 2017 were analysed (n = 3616). Because the proportional hazards assumption was violated, a multivariable Cox model restricted to the first 6 months and a multivariable landmark Cox model from ...
Tópico(s): Melanoma and MAPK Pathways
2020 - Elsevier BV | European Journal of Cancer
Michiel C.T. van Zeijl, Rawa K. Ismail, Liesbeth C. de Wreede, Alfonsus J.M. van den Eertwegh, Anthonius de Boer, Maaike van Dartel, Doranne L. Hilarius, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Marye J. Boers‐Sonderen, Jan‐Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, John B.A.G. Haanen, Michel W.J.M. Wouters,
Abstract The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision‐making. Analysis were performed on advanced melanoma patients diagnosed between 2014 and 2017 in the Netherlands, treated with immune‐ or targeted therapy, who met ≥1 trial exclusion criteria. These criteria were derived from the KEYNOTE‐006 and CHECKMATE‐067/‐066 phase III trials. Prognostic importance of factors associated with overall ...
Tópico(s): Cutaneous Melanoma Detection and Management
2020 - Wiley | International Journal of Cancer
Monique K. Van der Kooij, Marjolein J.A.L. Wetzels, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Marye J. Boers‐Sonderen, Miranda P. Dierselhuis, Jan Willem B. de Groot, Geke A.P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Michel W.J.M. Wouters, John B.A.G. Haanen, Alfonsus J.M. van den Eertwegh, Esther Bastiaannet, Ellen Kapiteijn,
Cutaneous melanoma is a common type of cancer in Adolescents and Young Adults (AYAs, 15–39 years of age). However, AYAs are underrepresented in clinical trials investigating new therapies and the outcomes from these therapies for AYAs are therefore unclear. Using prospectively collected nation-wide data from the Dutch Melanoma Treatment Registry (DMTR), we compared baseline characteristics, mutational profiles, treatment strategies, grade 3–4 adverse events (AEs), responses and outcomes in AYAs (n = 210) ...
Tópico(s): Melanoma and MAPK Pathways
2020 - Multidisciplinary Digital Publishing Institute | Cancers
Karlijn de Joode, Daphne W. Dumoulin, Jolien Tol, Hans M. Westgeest, Laurens V. Beerepoot, Franchette W.P.J. van den Berkmortel, Pim Mutsaers, Nico G. J. van Diemen, Otto Visser, Esther Oomen‐de Hoop, Haiko J. Bloemendal, Hanneke W.M. van Laarhoven, Lizza Hendriks, John B.A.G. Haanen, Elisabeth G.E. de Vries, Anne‐Marie C. Dingemans, Astrid A.M. van der Veldt, C.J. van Loenhout, Cor H. van der Leest, Annemarie Becker‐Commissaris, Jessica S.W. Borgers, F. Terhegggen, Ben E.E.M. van den Borne, L.J.C. van Warmerdam, L. van Leeuwen, Femke S. van der Meer, M. Tiemessen, D.M. van Diepen, Yarne Klaver, A.P. Hamberg, Eduard J. Libourel, Luc J. A. Strobbe, Marissa Cloos, Erica J. Geraedts, Jan C. Drooger, Raban Heller, Jan Willem B. de Groot, Jos A. Stigt, Veerle J. Nuij, Cordula Pitz, Marije Slingerland, Frank J. Borm, Brigitte C.M. Haberkorn, Susan C. van ‘t Westeinde, Maureen J.B. Aarts, J.W.G. van Putten, Mina Youssef, Geert A. Cirkel, Gerarda J.M. Herder, C. R. van Rooijen, Emanuel Citgez, Nicole P. Barlo, Béatrice Scholtes, Rutger H.T. Koornstra, Niels Claessens, Laura M. Faber, C.H. Rikers, R.A.W. van de Wetering, Gerald Veurink, B.W. Bouter, Ilse Houtenbos, Mathieu Bard, Karin H. Herbschleb, Elisabeth A. Kastelijn, Pepijn Brocken, Gea Douma, Mathilde Jalving, T. Jeroen N. Hiltermann, Olga C.J. Schuurbiers-Siebers, Karijn P.M. Suijkerbuijk, Anne S. R. van Lindert, Agnès J. van de Wouw, Vivian E. M. van Kampen‐van den Boogaart, Sandra D. Bakker, E. Looysen, A.L. Peerdeman, Wouter K. de Jong, Ester Siemerink, Ada Staal, Bas Franken, Wouter H. van Geffen, Gerben Bootsma,
Aim of the studyPatients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19.MethodsThis observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire ...
Tópico(s): Cancer survivorship and care
2020 - Elsevier BV | European Journal of Cancer
Michiel C.T. van Zeijl, Florine L. Boer, Mariëtte I.E. van Poelgeest, Alfons J.M. van den Eertwegh, Michel W.J.M. Wouters, Liesbeth C. de Wreede, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers‐Sonderen, Ellen Kapiteijn, John B.A.G. Haanen,
Mucosal melanoma (MM) is rare and has a poor prognosis. Since 2011, new effective treatments are available for advanced melanoma. It is unclear whether patients with mucosal melanoma equally benefit from these new treatments compared with patients with cutaneous melanoma (CM).Patients with advanced MM and CM diagnosed between 2013 and 2017 were included from a nationwide population-based registry - the Dutch Melanoma Treatment Registry. Overall survival (OS) was estimated with the Kaplan-Meier method ( ...
Tópico(s): CAR-T cell therapy research
2020 - Elsevier BV | European Journal of Cancer
Rik J. Verheijden, Anne M. May, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Alfonsus J.M. van den Eertwegh, Jan Willem B. de Groot, Marye J. Boers‐Sonderen, Jacobus J. M. van der Hoeven, Geke A.P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Michiel C.T. van Zeijl, Michel W.J.M. Wouters, John B.A.G. Haanen, Ellen Kapiteijn, Karijn P.M. Suijkerbuijk,
Abstract Purpose: Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related toxicity necessitating immunosuppressive treatment. Whether immunosuppression for toxicity impacts survival is largely unknown. Experimental Design: Using data from the prospective nationwide Dutch Melanoma Treatment Registry (DMTR), we analyzed the association between severe toxicity and overall survival (OS) in 1,250 patients with advanced melanoma who were treated with immune checkpoint ...
Tópico(s): Immunotherapy and Immune Responses
2020 - American Association for Cancer Research | Clinical Cancer Research
Anouk Jochems, Monique K. Van der Kooij, Marta Fiocco, Maartje G. Schouwenburg, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel, Christian U. Blank, Alfonsus J.M. van den Eertwegh, M Franken, Jan‐Willem B. de Groot, John B.A.G. Haanen, Geke A.P. Hospers, Rutger H.T. Koornstra, Wim H.J. Kruit, Marieke W.J. Louwman, Djura Piersma, Rozemarijn S. van Rijn, Karijn P.M. Suijkerbuijk, Albert J. ten Tije, Gerard Vreugdenhil, Michel W.J.M. Wouters, Michiel C.T. van Zeijl, Koos J.M. van der Hoeven, Ellen Kapiteijn,
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63–14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI ...
Tópico(s): Brain Metastases and Treatment
2019 - Multidisciplinary Digital Publishing Institute | Cancers
Maartje G. Schouwenburg, Karijn P.M. Suijkerbuijk, Rutger H.T. Koornstra, Anouk Jochems, Michiel C.T. van Zeijl, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Maureen J.B. Aarts, Alexander C.J. van Akkooi, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Wim H.J. Kruit, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Jacobus J. M. van der Hoeven, Michel W.J.M. Wouters,
The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with normalized LDH after targeted therapy could benefit from subsequent treatment with immune checkpoint inhibitors (ICI). Data from all patients with BRAF-mutant metastatic melanoma with a highly elevated serum LDH at baseline (≥2× upper limit of normal) receiving ...
Tópico(s): CAR-T cell therapy research
2019 - Multidisciplinary Digital Publishing Institute | Cancers